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Impending?Widespread use of pneumococcal conjugate vaccines
(PCVs) has substantially decreased the incidence of pneu-
mococcal diseases, such as pneumonia, meningitis, and
acute otitis media in several parts of the world. The abso-
lute number of cases of Streptococcus pneumoniae
bacteremia and its proportion among all bacteremia cases
in children has also significantly decreased. Routine PCV7
implementation has reduced 84% of S. pneumoniae
bacteremia in Northern California, USA, and 57.5% of occult
bacteremia caused by S. pneumoniae in Spain.1,2 Although
PCVs have been very successful, two problems remain. One
is breakthrough infections caused by vaccine serotypes,
especially serotypes 19A,3 and the other is the so-called
“serotype replacement”. S. pneumoniae serotype distri-
butions have significantly changed. While PCV serotypes
were nearly eliminated by PCV use, non-PCV serotypes have
increased. For example, serotypes 24F, 22F, 8, and 15A
have been encountered more frequently in countries using
PCV13.4
Ribitzky-Eisner et al5 recently investigated the epide-
miological and microbiological characteristics of pure
bacteremia without any identifiable focus in children aged
3e36 months in south Israel. They found that PCV13
serotyped-occult bacteremia completely disappeared
approximately 1 year after PCV13 implementation. How-
ever, their study did not show a significant decrease in the
total number of occult bacteremia cases caused by all S.
pneumoniae serotypes after PCV implementation, sug-
gesting a compensatory increase in non-PCV13 serotypes.
An earlier study in Israel showed that PCV7 serotype-
invasive pneumococcal diseases (IPDs) had decreased
significantly by 43% and 81% after PCV7 and PCV13 imple-
mentations, respectively. Meanwhile, the overall number of
IPD cases decreased at a slower rate: all serotype-IPD
decreased by 23% and 42% after PCV7 and PCV13 imple-
mentations, respectively.6 A compensatory increase of non-
PCV13 serotypes accounts for the discrepancy observed
between the magnitudes of decrease in PCV13 and allhttp://dx.doi.org/10.1016/j.pedneo.2015.08.012
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).serotypes. Another study in Israel confirmed a two-fold in-
crease in bacteremia caused by non-PCV13 serotypes after
PCV implementation.7
This is not an uncommon phenomenon in countries
where massive immunization programs with PCV are
implemented. It is generally believed that the extent of
increase in nonvaccine-type pneumococcal diseases (IPDs
or others) is far lesser than the decrease in vaccine-type
diseases, resulting in a net decrease in pneumococcal dis-
eases. The study by Ribitzky-Eisner et al,5 however, showed
that the decrease in occult bacteremia caused by vaccine-
type S. pneumoniae might have been well replaced by the
increase in cases of occult bacteremia caused by
nonvaccine-type S. pneumoniae, resulting in a steady total
number of occult bacteremia cases. Further observation is
needed to exclude the possibility that significant serotype
replacement is occurring in certain parts of the world and
among certain groups of patients.
Another interesting finding of the study by Ribitzky-Eisner
et al5 is thatmore thanhalf (52.8%) of thepatientswith occult
bacteremia did not receive any antibiotic treatment at
discharge from the emergency room, suggesting that cases
included in this study were clinically milder. Could it be
possible that the newly emerging serotypes are less virulent
than traditional serotypes and lead to less severe clinical
conditions? Serotype replacement might be less evident if
attention is paid to more severe conditions, such as IPDs,
which are the major illnesses from which current serotype
distributionswere derived. Thenumberof these patientswho
developed more severe conditions, such as meningitis and
septic shock, after leaving the emergency room is unknown.
The story of pneumococcal serotype evolution with and
without the influences of PCV usage is not over. Although
replacement is inevitable when vaccine serotypes are pre-
vented by mass PCV usage, to date there has been no evi-
dence of any new emerging superstar serotypes, such as
serotype 1 or 19A observed in early years. The importance of
continuousmonitoring, however, cannot be overemphasized.Elsevier Taiwan LLC. This is an open access article under the CC BY-
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